SCHEMBL8344735

SCHEMBL8344735

CCOC(=O)C1=C(C)N(c2cccc(N)c2)C(=O)NC1c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 5/20 0.61
▸ ELANE P08246 5/20 0.61
▸ MAPT P10636 1/20 0.51
▸ POLB P06746 1/20 0.48
▸ LMNA P02545 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ TRPC5 Q9UL62 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ HTT P42858 1/20 0.46
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ ALOX12 P18054 1/20 0.43
▸ ADORA2B P29275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8344050 0.90 MAPT (0.62) CYP2C9ELANEMAPTPOLBLMNA
SCHEMBL13412241 0.85 MAPT (0.69) CYP2C9ELANEMAPTALDH1A1HTT
SCHEMBL8050837 0.83 ELANE (0.79) CYP2C9ELANEMAPTPOLBLMNA
SCHEMBL2888375 0.79 ELANE (0.69) CYP2C9ELANEMAPTLMNATSHR
SCHEMBL8220635 0.78 ELANE (0.70) CYP2C9ELANEMAPTLMNAALDH1A1
SCHEMBL2888564 0.78 ELANE (0.79) CYP2C9ELANEMAPTLMNAALDH1A1
SCHEMBL9914387 0.78 ELANE (0.79) CYP2C9ELANEMAPTPOLBLMNA
SCHEMBL2887923 0.78 ELANE (0.79) CYP2C9ELANEMAPTLMNAALDH1A1
SCHEMBL2894486 0.77 ELANE (0.78) CYP2C9ELANEMAPTPOLBLMNA
SCHEMBL2896028 0.77 ELANE (0.77) CYP2C9ELANEMAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004024700-A1 PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES BAYER HEALTHCARE AG (DE) 2004-03-25 — — WO disclosed
Send feedback